RNU6-678P

Across TCGA pan-cancer cohorts, RNU6-678P RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated RNU6-678P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-678P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-678P expression acts as an unfavorable survival marker, although some lineages such as UCS and SKCM show a favorable association.

LIHC, KIRC, and COAD are the cancer types where RNU6-678P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Quartile	All	0.285	0.488	<.001	64	view →
KIRC	DFS	Tertile	All	0.457	0.708	<.001	62	view →
COAD	OS	Tertile	II,III,IV	0.421	0.689	<.001	35	view →
UCS	DFS	Tertile	III,IV	0.539	0.131	.007	28	view →
ACC	DFS	Quartile	All	0.237	0.639	.007	28	view →
SKCM	DFS	Tertile	III,IV	0.736	0.542	.006	22	view →
PRAD	DFS	Median	All	0.839	0.926	.002	22	view →
SARC	OS	Median	All	0.380	0.635	.005	16	view →
KIRP	DFS	Median	All	0.878	0.635	.020	13	view →
CESC	DFS	Quartile	II,III,IV	0.384	0.787	.009	12	view →
LUAD	OS	Quartile	III,IV	0.666	0.203	.019	12	view →
PAAD	DFS	Median	II,III,IV	0.476	0.280	.010	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

RNU6-678P–LIHC (DFS)

Open the LIHC breakdown →